Menarini
As of the edition of 20 October 2026, Menarini runs 4 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Meropenem | none listed | 0 |
| Ranolazine | none listed | 4 |
| Oritavancin | Ends 2035 (patent) | 0 |
| Vaborbactam | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Menarini needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 2 trials led
- Lungs and airways: 2 trials led
- Ear, nose and throat: 1 trials led